
Genetic testing for prostate cancer is rapidly growing and is increasingly driven by precision medicine. Rates of germline pathogenic variants have been reported in up to 15% of men with prostate cancer, particularly in metastatic disease. Genetic testing results could uncover options for precision therapy and a spectrum of hereditary cancer-predisposition syndromes with unique clinical features with complex management options. Thus, the pre-test discussion, whether delivered by genetic counsellors or by health-care professionals in hybrid models, involves information on hereditary cancer risk. Understanding precision medicine, personalized cancer risk management and syndrome-related cancer risk management are important to develop collaborative strategies with genetic counselling for optimal care of patients and their families.
Like
Save
Share